NexGel Inc (NXGL)

NexGel Secures Regenerative Biomaterials Portfolio From Celularity in Landmark TransactionMarch 10, 2026 10:37 AM
IH Market News
NEXGEL, Inc. (NASDAQ:NXGL) has signed an asset purchase and exclusive licensing agreement with Celularity, Inc. to obtain rights to Celularity’s commercial-stage regenerative biomaterials portfolio, the companies announced. The products focus on applications including tendon repair, skin grafts and bone regeneration.The agreement, dated March 6, 2026, carries a total potential value of up to $35 million. It includes an upfront payment of $15 million in cash and up to $20 million in additional milestone-based payments. The transaction may also involve manufacturing arrangements and a sublease agreement. Completion of the deal is contingent upon NEXGEL securing financing to cover the initial payment.Publicly disclosed on March 10, 2026, the acquisition is described by NEXGEL as the most significant development in the company’s history. Management expects the deal to approximately triple annual revenue to around $35 million and move the company into profitability once the transaction closes.The portfolio includes six established regenerative biomaterial products that are already generating revenue, have insurance reimbursement coverage and have been used clinically for more than a decade. In addition, the acquisition includes a development pipeline featuring three planned 510(k) regulatory submissions expected in 2026, 2027 and 2028. The transaction will also bring in a commercial and scientific team with experience in the field, which NEXGEL believes will help expand its sales capabilities and strengthen its position in the medical technology sector.To support the transaction, NEXGEL plans to complete approximately $14.9 million in additional financing during the first half of 2026. The proceeds are expected to help fund the upfront payment and support integration of the acquired assets.The company also said it is in discussions with an accredited institutional investor regarding a potential equity line of credit of up to $100 million in newly issued common shares. Such a facility could provide flexible capital to support future expansion and help scale a combined regenerative biomaterials and hydrogel platform across multiple healthcare and consumer markets.



More about NexGel Inc



NEXGEL, Inc., based in Langhorne, Pennsylvania, develops and supplies healthcare, beauty and over-the-counter products using high-water-content hydrogel technologies designed to be gentle on the skin. The company has more than 20 years of experience producing electron-beam, cross-linked hydrogels.Its portfolio includes brands such as SilverSeal, Hexagels, Turfguard, Kenkoderm and Silly George, while it also manufactures products for several major consumer healthcare companies through contract partnerships.NEXGEL operates at the intersection of consumer health and medical technology, applying its hydrogel platform across wound care, dermatology and cosmetic applications. Its products are sold both under its own brands and through commercial partners, positioning the company as a specialized materials provider in both regulated medical markets and the broader OTC sector.NexGel stock price

Original: NexGel Secures Regenerative Biomaterials Portfolio From Celularity in Landmark Transaction

looking for another run!

3 month uptrend,increasing volume surges, great indicator of continuing up

Thru $5 is good,could get interesting!

Waking up again!

NXGL 5 BUCKS RING A DING!!

NXGL LETS SEE 5 BUCKS

NXGL MASSIVE BREAK

NXGL BEAUTIFUL WEEKLY BREAK OUT

NXGL...MY NEXT BIO BEAST READY TO ROAR THROUGH WALL STREET

NXGL, new 52 week high

Looks like flipping the warrents would have been good last few days

Expecting earnings report around Nov 14th...🤪

Hey 81vette, expecting earnings' NEWS any moment/day.
Also anticipating a PROFIT which should send $NXGL, I'm thinking...😺

Hey bro,good to see you,yes it’s been stairstepping up nicely since early 2023
Thanks for reminding me about it!!

Looking for 100% gain from here (2.80) when earnings are released around Nov. 14, 2024.

As of August 13, 2024, the registrant had 6,324,266 shares of common stock outstanding.



$NXGL



👉️ NXGL 10Q Period Ending June 30, 2024

NXGL under $3

Winner winner chicken dinner!!

Looking good!

Anybody home?

NXGL looking great! Solidly over $2 and volume increasing. Keep it going

Ended @New 52 week high,blue sky babe!! Enjoy the weekend everyone!!

contracts with pro sports teams will make brand huge,building a great company,investment in packaging plant was wise

For the first quarter of 2023, revenue totaled $620 thousand and increased by $224 thousand, or 56.6%, compared to $396 thousand for the same period the year prior. The increase in overall revenues was primarily due to sales growth in both contract manufacturing and branded products. Revenue during the first quarter of 2023 includes one full month of revenue contribution from the Company’s newly formed joint venture with C.G. Laboratories.first quarter we delivered 56.6% revenue growth year-over-year, driven by increased sales in contract manufacturing and branded consumer products. We also started to see contribution in March from our new joint venture with CG Labs. During the quarter, we launched several new products and invested strategically in sales and marketing to support those launches. We are already starting to see the financial returns from these investments in the second quarter, as well as from our new JV.” “Based on the dynamic changes to our business, which include the March 1 joint venture, I feel it’s important to provide a one-time exception to our policy of not providing guidance. Based on these developments and our progress to date, we are projecting $1.0 million in revenue for the second quarter of 2023, an increase of 78.2% year-over-year. Complementing this, we had approximately $5.8 million in cash and cash equivalents at quarter-end, which gives us sufficient runway to operate and the ability to be opportunistic about further potential investments to accelerate our growth.”Acquired a 50% interest in a newly formed joint venture (“JV”), CG Converting and Packaging, LLC, with C.G. Laboratories Inc. (“CG Labs”) for its converting and packaging business.
Executed a supply agreement with a large new customer relating to a new consumer product.Launched advertising and marketing initiative, which has increased branded product sales.

watch demand,next move up thru 52 week high,very low supply atm

GOLDEN CROSS is best indicator of long bulls,follow the money is the saying

eps q/q up 60%,is why moving up,big profit coming,great future $ deals,expect institutions loading long,way undervalued@ 10M mkt cap

GOLDEN CROSS now,thru triple top res.,52week high>$2.00,then blue sky

4M float,5M o/s,.52%short,buy vol 15X ave,not optionable,shares borrow ava. dropped 400% with pre-mkt volume,easily could go ZERO BORROW with this low float/os